Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
The Role of In Silico Regional Deposition Modelling and Pharmacokinetic Profiling in the Development of a Generic Tiotropium Dry Powder Inhaler
Nanopharm explores In Silico methods in the development of a Generic Tiotropium Dry Powder Inhaler (DPI). Learn how drug absorption is impacted.
Regional Deposition in Generic Dry Powder Inhalers
Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.
Alternative regulatory path for generic Respiratory Products
Explore Nanopharm’s SmartTrack, an alternative solution for FDA approval of generic inhalation drug delivery products.
Challenges in OINDPs Achieving Q3 Equivalence
Nanopharm review the bioequivalence challenges for OINDPs by achieving Q3 structural equivalence.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
